BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge - 2The Secret Destinations Amex Says Will Be More Popular Than Bali by 2026
- 3Home Remodel Administrations: Change Your Residing Space
- 4One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 5The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Best Streaming Gadget for Your Home Theater
- The Most Paramount Crossroads in Olympic History
- Parents who delay baby's first vaccines also likely to skip measles shots
- Aid sent by ambulance to Ukraine front line
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- Pick Your Top Method for starting the Morning
- The 10 Most Famous Works of art Ever
